PHARMALA BIOTECH HOLDINGS IN

Pharmala Biotech climbs 2.86% amid talks of a major oncology partnership – a low‑priced entry into Canada’s biotech scene with potential upside from upcoming trials.

Pharmala Biotech shares surge 9.38% in a single day, driving investor confidence in its oncology‑focused biotech strategy and potential breakthrough therapies.

Pharmala Biotech (MDMA.CN) edges up 3.2% as its oncology pipeline and strategic R&D partnerships promise upside in a volatile biotech market.